Literature DB >> 17443458

Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis.

Estella M Geraghty1, Bryan Ristow, Shelley M Gordon, Paul Aronowitz.   

Abstract

We describe a 45-year-old woman receiving infliximab therapy for rheumatoid arthritis who developed an overwhelming Plasmodium falciparum infection with cerebral malaria. Physicians should be aware that patients receiving tumor necrosis factor inhibitors, such as infliximab, may be at increased risk of life-threatening malarial infections.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17443458     DOI： 10.1086/515402

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Inflammatory bowel disease in travelers: choosing the right vaccines and check-ups.

Authors:  Maria Esteve; Carme Loras; Ester García-Planella
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 2.  [Vaccination prior to travelling for patients with rheumatic diseases].

Authors:  B Ehrenstein
Journal:  Z Rheumatol       Date:  2011-06       Impact factor: 1.372

3.  Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

Authors:  A R Pérez; G H Fontanella; A L Nocito; S Revelli; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

4.  Infliximab in the treatment of plaque type psoriasis.

Authors:  Rosita Saraceno; Andrea Saggini; Lucia Pietroleonardo; Sergio Chimenti
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-03

5.  Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria.

Authors:  Gabriela Minigo; Tonia Woodberry; Kim A Piera; Ervi Salwati; Emiliana Tjitra; Enny Kenangalem; Ric N Price; Christian R Engwerda; Nicholas M Anstey; Magdalena Plebanski
Journal:  PLoS Pathog       Date:  2009-04-24       Impact factor: 6.823

Review 6.  The global pipeline of new medicines for the control and elimination of malaria.

Authors:  Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

Review 7.  Management of infections in critically ill returning travellers in the intensive care unit-II: clinical syndromes and special considerations in immunocompromised patients.

Authors:  Jordi Rello; Oriol Manuel; Philippe Eggimann; Guy Richards; Christian Wejse; Jorgen Eskild Petersen; Kai Zacharowski; Hakan Leblebicioglu
Journal:  Int J Infect Dis       Date:  2016-04-28       Impact factor: 3.623
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.